Denali Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 4 Sell calls were followed by a 25% average decline over the next quarter.
- Recent price momentum is -9.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -59.5% | Better than 9% |
| Net margin | -43.9% | Better than 9% |
| Return on equity | -45.7% | Better than 10% |
| Return on invested capital | -47.7% | Better than 6% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -26.0% | Better than 22% |
| 6-month return | -1.0% | Better than 54% |
| 12-month return (ex latest month) | 3.7% | Better than 38% |
| Distance below 52-week high | 32.4% | Better than 38% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 9.2x | Better than 93% |
| Debt to assets | 3.2% | Better than 84% |
| Free cash flow / net income | 580.7% | Better than 94% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 91.5% | Better than 81% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 18.20
- Open
- 17.97
- Day range
- 17.92 - 18.85
- Avg price
- 18.49
- Volume
- 2.63M
- Turnover
- 48.66M
- Turnover ratei
- 1.69%
- Volume ratioi
- 1.96
- Amplitudei
- 5.11%
- 52-week rangei
- 15.34 - 27.30
Valuation
- P/Ei
- -6.21
- P/E (TTM)i
- -10.73
- P/Bi
- 3.19
- EPSi
- -2.97
- Book value / shi
- 5.78
- Net profit
- -476.06M
- Net assets
- 926.32M
Share structure
- Market cap
- 2.96B
- Float capi
- 2.87B
- Shares out
- 160.29M
- Float sharesi
- 155.54M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-12-08
32.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-472.62K net over the window
Short interest
- Shares short
- 14.69M
- % of floati
- 9.19%
- Days to coveri
- 9.91
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Denali Therapeutics (DNLI)?
Denali Therapeutics last traded at 18.45. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Denali Therapeutics's market cap?
About 2.96B.
What is the P/E ratio of Denali Therapeutics?
The trailing twelve-month P/E is -10.73. The Valuation tab shows it against the stock's own five-year range.
Does Denali Therapeutics pay a dividend?
Denali Therapeutics does not currently pay a regular dividend.
Is Denali Therapeutics a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 35.33, which implies 91.5% upside from the current price. This is not investment advice.
What is Denali Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Denali Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Denali Therapeutics discussion 0 comments